Similar to these MCL studies, our group and others have also developed ibrutinib-resistant DLBCL cells and identified upregulation of PI3K-AKT signaling in resistant cells, which can be overcome by selective PI3K isoform inhibitors treatment [88, 89]. The gene discussed is PIK3CD; the disease is diffuse large B-cell lymphoma.